AAVantgarde is now initiating ‘CELESTE’, a first-in-human Phase 1/2 clinical trial in the United States, to evaluate the safety, tolerability, and initial efficacy of AAVB-039 in patients with ...

Similar data from Social Security Scotland indicates there are now 2,010 people receiving ADP for an eye condition. An estimated 188,000 people in Scotland are affected by some form of sight loss with ...

If approved, MCO-010 would be the first treatment to restore vision in legally blind RP patients without needing genetic ...